



Dejando huella en la
Industria de la Salud Animal

MICROFLOX 100

Enrofloxacin

Broad-spectrum antibiotic

MICROFLOX 100

REGISTRATION NUMBER Q-7972-072

Each tablet contains:

Enrofloxacin 100 mg

Excipient cbp.....1 tablet



Presentation: MICROFLOX 100 Box with 20 tablets of 100 mg.

Description:

Microflox 100 contains micronized enrofloxacin, which allows better digestive absorption, bioavailability, faster tissue penetration and better liposolubility. It acts against Gram positive bacteria, Gram negative Mycoplasma spp, and some Rickettsias.

It inhibits cell division and bacterial growth rate, prevents tissue colonization and promotes phagocytosis.

INDICATIONS:

It is recommended for otitis externa, septicemias, enterobacteria, prevention and treatment of osteomyelitis, skin infections, respiratory urogenital, prostate and wounds. It has a post-antibiotic effect on Staphylococcus intermedius, Enterobacter spp, Pseudomonas aeruginosa, Klebsiella pneumoniae, Pasteurella multocida, Escherichia coli, Salmonella typhimurium, Streptococcus aureus and Rickettsia rickettsii.

Enrofloxacin is characterized by good antimicrobial activity, even against microorganisms that are not very susceptible or resistant to other antimicrobials commonly used in animals. It has an excellent pharmacokinetic behavior of easy administration, almost complete absorption and a tissue distribution that guarantees minimum inhibitory concentrations (MIC) against the microorganisms that cause most diseases in animals. Its therapeutic index is high, and it can be administered without major problems in combination therapies with other drugs. It represents, without a doubt, an excellent tool for clinical management in veterinary medicine.


Chemical structure

Enrofloxacin is a fluorquinolone derived from nalidixic acid, it has a basic chemical nucleus called "dihydroquinoline" or 4-quinolone ring.

It has a low molecular weight, which favors its tissue penetration. At its isoelectric point it has the lowest solubility and is highly lipophilic.

Mechanism of action

It is a concentration dependent antibiotic and can also act as a time dependent on gram+ bacteria. It inhibits DNA-spin, a bacterial enzyme involved in most biological processes that compromise DNA, such as transcription, recombination, replication and DNA repair. DNA-spinyase is a type II Topoisomerase, and is the only one of its kind capable of introducing a negative helical super-roll into the DNA molecule, playing a critical role in maintaining superhelical genomic density. They also inhibit IV topoisomerase, essential in the chromosomal segregation of prokaryotic cells.





Dejando huella en la
Industria de la Salud Animal

In some species of bacteria, such as *E. coli*, the main site of action is DNA-girase while in others, such as *S. aureus*, it is Topoisomerase IV. Considering that these enzymes have somewhat different functions, it is likely that bacteria differ in their responses according to what the point of action is.

Pharmacokinetics

Microflox 100 in dogs it is rapidly absorbed orally, with a bioavailability of 72%, approximately 83%, or close to 100% according to different authors, reaching maximum concentrations within 0.5 to 2 hours. It is also well absorbed orally in cats, with a bioavailability of almost 100%. Distribution volume of 2 to 4 liters per kg and excellent tissue penetration (including phagocytes).

Distribution

In most animal species the volume of distribution of Microflox 100 is high, being much higher than that reached by beta-lactams and aminoglycosides. It is mainly concentrated in saliva, nasal discharge; in mucosa, epithelium and bronchial secretion, as well as in the liver and urinary tract. They penetrate well into lung tissue, lining fluid and alveolar macrophages, resulting in concentrations greater than serum, arriving more quickly. After 12 hours of application the concentrations remained higher in the tissues than in the serum, with the highest values in bile and urine, later in decreasing order, in liver, kidneys, heart, lungs and spleen. The lowest concentrations were found in the brain.

Metabolism and excretion

Fluorquinolones are eliminated from the body mainly by hepatic metabolism and renal excretion. They are usually partially metabolized in the liver, and excreted in bile and urine at high concentrations of active drug (unchanged drug or active metabolite). The common metabolic pathways of these agents are dealkylation, glucuronization, oxidation, sulfoxidation, acetylation, and piperazin ring rupture. In animals renal excretion is variable, although glomerular filtration occurs for the unattached fraction, and also active tubular secretion. Glomerular filtration and tubular secretion allow high urinary concentrations to be reached. The percentage of elimination through bile varies between species. Trans-epithelial elimination through the gastrointestinal wall generates high concentrations at colonization sites of pathogenic bacteria, and undoubtedly contributes to the high efficacy of this antimicrobial to bacterial enteritis. There are indications that entero-hepatic circulation may occur. Enrofloxacin is partially metabolized to ciprofloxacin, which is responsible for a considerable portion of the antimicrobial activity.

SPECIES

Canines and Felines

DOSES:

MICROFLOX 100:

- 5 mg / kg of weight which is equivalent to one tablet for every 20 kg of weight per day, for 5 to 7 days, depending on the degree of infection, location and pathogen involved, at the Veterinarian discretion.



Dejando huella en la
Industria de la Salud Animal

ROUTE OF ADMINISTRATION: Oral.

Interactions:

It is synergistic with aminoglycosides, 3rd generation cephalosporins and broad-spectrum penicillins.

When used together with metronidazole, it increases their spectrum, for polybacterial infections

Antacids, some metal ions such as calcium, cobalt copper, magnesium, aluminum, silver, zinc reduce the absorption of fluoroquinolones.

Adverse effects

In dogs under 28 days and in animals in gestation and in general in growing animals, it should be avoided because abnormalities in cartilage may occur. At doses of 5-10 mg/kg in dogs and cats for 10 days no adverse effects have been found. The most common adverse effect is nausea. In cats at doses of 20mg/kg can cause degeneration or retinal changes, mydriasis, vision loss. At the gastrointestinal level in dogs and cats anorexia, vomiting, increased liver enzymes diarrhea may occur; neurologically: ataxia, depression, lethargy.

WARNINGS AND/OR RESTRICTIONS:

Any enrofloxacin produces erosion of the articular cartilage, so its use in growing animals is not recommended. Do not exceed the recommended dose because it decreases its effectiveness and increases genotoxicity on eukaryotic cells.

Keep in a dry place, cool at no more than 30°C and protected from light. Do not leave it within reach of children, pets and disabled people. Any unused veterinary medicinal product, residues derived thereto and empty containers must be disposed of safely and in accordance with local regulations, avoiding contaminating water sources. Product for exclusive use in Veterinary Medicine.

MEDICAL PRESCRIPTION IS NECESSARY FOR SELL

CONSULT WITH YOUR VETERINARIAN

Exclusive literature for Veterinarians. Keep out of reach of children.

Responsible for content: Technical Department. farmacovigilancia@petspharma.com.

Made in Mexico by:

Pet's Pharma de México S.A. de C.V. Av. Sor Juana Inés de la Cruz # 580, State of Mexico, C.P. 57000 Tel. 55 57433839, 55 5736-4742

Website: www.petspharma.com.mx

Also find us on Facebook, Instagram, YouTube and LinkedIn